Global Biomarker Technologies

Biomarker Technologies Comprehensive Study by Type (Safety Biomarkers, Efficacy Biomarkers (Predictive Biomarkers, Prognostic Biomarkers, Pharmacodynamic Biomarkers, Surrogate Biomarkers), Validation Biomarkers), Application (Diagnostics, Personalized Medicine, Drug Discovery and Development, Disease Risk Assessment, Others), Product (Consumables, Services, Software), Disease Indication (Cancer, Neurological Disorders, Cardiovascular Disorders, Immunological Disorders, Others) Players and Region - Global Market Outlook to 2028

Biomarker Technologies Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
The high prevalence of cancer is encouraging research initiatives, driving the growth of the market. Extensive research and technological advancements used for the development of biomarker technology-based clinical diagnostics are projected to be the key contributors to the market. A rising number of Contract Research Organizations (CROs) is anticipated to further fuel the demand. Biomarkers technology which is also known as molecular marker technology or signature molecule technology is used to check how the body responds to the treatment of any condition or disease. In simple words, they are used to examine organ functions and other health conditions. They are also used in imaging technology so that they can provide clear imaging of oncology tumors and other problems. They are also used in clinical studies to determine the effect and results of drugs in the early stage.This growth is primarily driven by Increasing Diagnostic Applications of Biomarkers Technologies .

AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Volume UnitN
Value UnitUSD (Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


The Biotechnology sector in the region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Thermo Fisher Scientific (United States), F. Hoffmann-La Roche Ltd (Switzerland), Agilent Technologies (United States), Roche (Switzerland), Danaher Corporation (United States), Merck Millipore (United States), Waters Corporation (United States), Shimadzu Corporation (Japan), Bio-Rad Laboratories (United States) and Meso Scale Diagnostics, LLC (United States), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
In November 2019, Merck and Personalis, a cancer genomics company, entered into a partnership to identify and develop novel clinical biomarkers for cancer therapies. Under the terms of the partnership, Merck plans to use Personalis’ newest cancer immunogenomics platform ImmunoID NeXT for clinical biomarker identification and development
In March 2020, F. Hoffmann-La Roche Ltd announced the approval by the US Food and Drug Administration (FDA) for its CINtec PLUS Cytology as the first biomarker-based triage test for women whose primary cervical cancer screening results are positive for the human papillomavirus (HPV) using the Cobas 4800 HPV TestThe global biomarkers technologies market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of the biomarkers market for global, Europe, North America, Asia Pacific, South America, and Middle East & Africa.

Regulatory Insights:
In the United States, the Food and Drug Administration (FDA) plays a significant role in regulating biomarker technologies. The FDA evaluates and approves biomarkers used in diagnostics, drug development, and personalized medicine. They provide guidance and establish regulatory pathways for biomarker-based tests and companion diagnostics.

Influencing Trend:
Surging Technological Advancements in Molecular Biology and Laboratory Technology and Rising Prevalence of Various Diseases

Market Growth Drivers:
Increasing Diagnostic Applications of Biomarkers Technologies and Increasing R&D Funding for Pharma and Biotech Companies

Challenges:
Proving the Clinical Validity in Biomarker-Based Tests

Restraints:
High Capital Investments and Low Cost-Benefit Ratio and Poorly Suited Regulatory and Reimbursement Systems

Opportunities:
Emerging Economies and New Initiatives for Biomarker Technology Research

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mainly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the market's growth. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Data Sources of Biomarker Technologies Market Study

Primary Collection: InMail, LinkedIn Groups, Survey Monkey, Google, and Other professional Forums are some of the mediums utilized to gather primary data through key industry participants and appointees, subject-matter experts, C-level executives of Biomarker Technologies Industry, among others including independent industry consultants, experts, to obtain and verify critical qualitative commentary and opinion and quantitative statistics, to assess future market prospects.

The primary interviews and data collected as per the below protocols:
• By Designation: C-Level, D-Level, Others
• By Company Type: Tier 1, Tier 2, Tier 3

Secondary Data Sources such as Annual reports, Press releases, Analyst meetings, Conference calls, Investor presentations, Management statements, and SEC filings of Biomarker Technologies players along with Regulatory Sites, Association, World bank, etc were used as sources secondary set of data.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Biomarker Technologies Study Sheds Light on
— The Biomarker Technologies Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Biomarker Technologies industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Biomarker Technologies industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Safety Biomarkers
  • Efficacy Biomarkers [Predictive Biomarkers, Prognostic Biomarkers, Pharmacodynamic Biomarkers, Surrogate Biomarkers]
  • Validation Biomarkers
By Application
  • Diagnostics
  • Personalized Medicine
  • Drug Discovery and Development
  • Disease Risk Assessment
  • Others
By Product
  • Consumables
  • Services
  • Software

By Disease Indication
  • Cancer
  • Neurological Disorders
  • Cardiovascular Disorders
  • Immunological Disorders
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Diagnostic Applications of Biomarkers Technologies
      • 3.2.2. Increasing R&D Funding for Pharma and Biotech Companies
    • 3.3. Market Challenges
      • 3.3.1. Proving the Clinical Validity in Biomarker-Based Tests
    • 3.4. Market Trends
      • 3.4.1. Surging Technological Advancements in Molecular Biology and Laboratory Technology
      • 3.4.2. Rising Prevalence of Various Diseases
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Biomarker Technologies, by Type, Application, Product, Disease Indication and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Biomarker Technologies (Value)
      • 5.2.1. Global Biomarker Technologies by: Type (Value)
        • 5.2.1.1. Safety Biomarkers
        • 5.2.1.2. Efficacy Biomarkers [Predictive Biomarkers, Prognostic Biomarkers, Pharmacodynamic Biomarkers, Surrogate Biomarkers]
        • 5.2.1.3. Validation Biomarkers
      • 5.2.2. Global Biomarker Technologies by: Application (Value)
        • 5.2.2.1. Diagnostics
        • 5.2.2.2. Personalized Medicine
        • 5.2.2.3. Drug Discovery and Development
        • 5.2.2.4. Disease Risk Assessment
        • 5.2.2.5. Others
      • 5.2.3. Global Biomarker Technologies by: Product (Value)
        • 5.2.3.1. Consumables
        • 5.2.3.2. Services
        • 5.2.3.3. Software
      • 5.2.4. Global Biomarker Technologies by: Disease Indication (Value)
        • 5.2.4.1. Cancer
        • 5.2.4.2. Neurological Disorders
        • 5.2.4.3. Cardiovascular Disorders
        • 5.2.4.4. Immunological Disorders
        • 5.2.4.5. Others
      • 5.2.5. Global Biomarker Technologies Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Biomarker Technologies: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Thermo Fisher Scientific (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Agilent Technologies (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Roche (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Danaher Corporation (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Merck Millipore (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Waters Corporation (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Shimadzu Corporation (Japan)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bio-Rad Laboratories (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Meso Scale Diagnostics, LLC (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Biomarker Technologies Sale, by Type, Application, Product, Disease Indication and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Biomarker Technologies (Value)
      • 7.2.1. Global Biomarker Technologies by: Type (Value)
        • 7.2.1.1. Safety Biomarkers
        • 7.2.1.2. Efficacy Biomarkers [Predictive Biomarkers, Prognostic Biomarkers, Pharmacodynamic Biomarkers, Surrogate Biomarkers]
        • 7.2.1.3. Validation Biomarkers
      • 7.2.2. Global Biomarker Technologies by: Application (Value)
        • 7.2.2.1. Diagnostics
        • 7.2.2.2. Personalized Medicine
        • 7.2.2.3. Drug Discovery and Development
        • 7.2.2.4. Disease Risk Assessment
        • 7.2.2.5. Others
      • 7.2.3. Global Biomarker Technologies by: Product (Value)
        • 7.2.3.1. Consumables
        • 7.2.3.2. Services
        • 7.2.3.3. Software
      • 7.2.4. Global Biomarker Technologies by: Disease Indication (Value)
        • 7.2.4.1. Cancer
        • 7.2.4.2. Neurological Disorders
        • 7.2.4.3. Cardiovascular Disorders
        • 7.2.4.4. Immunological Disorders
        • 7.2.4.5. Others
      • 7.2.5. Global Biomarker Technologies Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Biomarker Technologies: by Type(USD Million)
  • Table 2. Biomarker Technologies Safety Biomarkers , by Region USD Million (2017-2022)
  • Table 3. Biomarker Technologies Efficacy Biomarkers [Predictive Biomarkers, Prognostic Biomarkers, Pharmacodynamic Biomarkers, Surrogate Biomarkers] , by Region USD Million (2017-2022)
  • Table 4. Biomarker Technologies Validation Biomarkers , by Region USD Million (2017-2022)
  • Table 5. Biomarker Technologies: by Application(USD Million)
  • Table 6. Biomarker Technologies Diagnostics , by Region USD Million (2017-2022)
  • Table 7. Biomarker Technologies Personalized Medicine , by Region USD Million (2017-2022)
  • Table 8. Biomarker Technologies Drug Discovery and Development , by Region USD Million (2017-2022)
  • Table 9. Biomarker Technologies Disease Risk Assessment , by Region USD Million (2017-2022)
  • Table 10. Biomarker Technologies Others , by Region USD Million (2017-2022)
  • Table 11. Biomarker Technologies: by Product(USD Million)
  • Table 12. Biomarker Technologies Consumables , by Region USD Million (2017-2022)
  • Table 13. Biomarker Technologies Services , by Region USD Million (2017-2022)
  • Table 14. Biomarker Technologies Software , by Region USD Million (2017-2022)
  • Table 15. Biomarker Technologies: by Disease Indication(USD Million)
  • Table 16. Biomarker Technologies Cancer , by Region USD Million (2017-2022)
  • Table 17. Biomarker Technologies Neurological Disorders , by Region USD Million (2017-2022)
  • Table 18. Biomarker Technologies Cardiovascular Disorders , by Region USD Million (2017-2022)
  • Table 19. Biomarker Technologies Immunological Disorders , by Region USD Million (2017-2022)
  • Table 20. Biomarker Technologies Others , by Region USD Million (2017-2022)
  • Table 21. South America Biomarker Technologies, by Country USD Million (2017-2022)
  • Table 22. South America Biomarker Technologies, by Type USD Million (2017-2022)
  • Table 23. South America Biomarker Technologies, by Application USD Million (2017-2022)
  • Table 24. South America Biomarker Technologies, by Product USD Million (2017-2022)
  • Table 25. South America Biomarker Technologies, by Disease Indication USD Million (2017-2022)
  • Table 26. Brazil Biomarker Technologies, by Type USD Million (2017-2022)
  • Table 27. Brazil Biomarker Technologies, by Application USD Million (2017-2022)
  • Table 28. Brazil Biomarker Technologies, by Product USD Million (2017-2022)
  • Table 29. Brazil Biomarker Technologies, by Disease Indication USD Million (2017-2022)
  • Table 30. Argentina Biomarker Technologies, by Type USD Million (2017-2022)
  • Table 31. Argentina Biomarker Technologies, by Application USD Million (2017-2022)
  • Table 32. Argentina Biomarker Technologies, by Product USD Million (2017-2022)
  • Table 33. Argentina Biomarker Technologies, by Disease Indication USD Million (2017-2022)
  • Table 34. Rest of South America Biomarker Technologies, by Type USD Million (2017-2022)
  • Table 35. Rest of South America Biomarker Technologies, by Application USD Million (2017-2022)
  • Table 36. Rest of South America Biomarker Technologies, by Product USD Million (2017-2022)
  • Table 37. Rest of South America Biomarker Technologies, by Disease Indication USD Million (2017-2022)
  • Table 38. Asia Pacific Biomarker Technologies, by Country USD Million (2017-2022)
  • Table 39. Asia Pacific Biomarker Technologies, by Type USD Million (2017-2022)
  • Table 40. Asia Pacific Biomarker Technologies, by Application USD Million (2017-2022)
  • Table 41. Asia Pacific Biomarker Technologies, by Product USD Million (2017-2022)
  • Table 42. Asia Pacific Biomarker Technologies, by Disease Indication USD Million (2017-2022)
  • Table 43. China Biomarker Technologies, by Type USD Million (2017-2022)
  • Table 44. China Biomarker Technologies, by Application USD Million (2017-2022)
  • Table 45. China Biomarker Technologies, by Product USD Million (2017-2022)
  • Table 46. China Biomarker Technologies, by Disease Indication USD Million (2017-2022)
  • Table 47. Japan Biomarker Technologies, by Type USD Million (2017-2022)
  • Table 48. Japan Biomarker Technologies, by Application USD Million (2017-2022)
  • Table 49. Japan Biomarker Technologies, by Product USD Million (2017-2022)
  • Table 50. Japan Biomarker Technologies, by Disease Indication USD Million (2017-2022)
  • Table 51. India Biomarker Technologies, by Type USD Million (2017-2022)
  • Table 52. India Biomarker Technologies, by Application USD Million (2017-2022)
  • Table 53. India Biomarker Technologies, by Product USD Million (2017-2022)
  • Table 54. India Biomarker Technologies, by Disease Indication USD Million (2017-2022)
  • Table 55. South Korea Biomarker Technologies, by Type USD Million (2017-2022)
  • Table 56. South Korea Biomarker Technologies, by Application USD Million (2017-2022)
  • Table 57. South Korea Biomarker Technologies, by Product USD Million (2017-2022)
  • Table 58. South Korea Biomarker Technologies, by Disease Indication USD Million (2017-2022)
  • Table 59. Taiwan Biomarker Technologies, by Type USD Million (2017-2022)
  • Table 60. Taiwan Biomarker Technologies, by Application USD Million (2017-2022)
  • Table 61. Taiwan Biomarker Technologies, by Product USD Million (2017-2022)
  • Table 62. Taiwan Biomarker Technologies, by Disease Indication USD Million (2017-2022)
  • Table 63. Australia Biomarker Technologies, by Type USD Million (2017-2022)
  • Table 64. Australia Biomarker Technologies, by Application USD Million (2017-2022)
  • Table 65. Australia Biomarker Technologies, by Product USD Million (2017-2022)
  • Table 66. Australia Biomarker Technologies, by Disease Indication USD Million (2017-2022)
  • Table 67. Rest of Asia-Pacific Biomarker Technologies, by Type USD Million (2017-2022)
  • Table 68. Rest of Asia-Pacific Biomarker Technologies, by Application USD Million (2017-2022)
  • Table 69. Rest of Asia-Pacific Biomarker Technologies, by Product USD Million (2017-2022)
  • Table 70. Rest of Asia-Pacific Biomarker Technologies, by Disease Indication USD Million (2017-2022)
  • Table 71. Europe Biomarker Technologies, by Country USD Million (2017-2022)
  • Table 72. Europe Biomarker Technologies, by Type USD Million (2017-2022)
  • Table 73. Europe Biomarker Technologies, by Application USD Million (2017-2022)
  • Table 74. Europe Biomarker Technologies, by Product USD Million (2017-2022)
  • Table 75. Europe Biomarker Technologies, by Disease Indication USD Million (2017-2022)
  • Table 76. Germany Biomarker Technologies, by Type USD Million (2017-2022)
  • Table 77. Germany Biomarker Technologies, by Application USD Million (2017-2022)
  • Table 78. Germany Biomarker Technologies, by Product USD Million (2017-2022)
  • Table 79. Germany Biomarker Technologies, by Disease Indication USD Million (2017-2022)
  • Table 80. France Biomarker Technologies, by Type USD Million (2017-2022)
  • Table 81. France Biomarker Technologies, by Application USD Million (2017-2022)
  • Table 82. France Biomarker Technologies, by Product USD Million (2017-2022)
  • Table 83. France Biomarker Technologies, by Disease Indication USD Million (2017-2022)
  • Table 84. Italy Biomarker Technologies, by Type USD Million (2017-2022)
  • Table 85. Italy Biomarker Technologies, by Application USD Million (2017-2022)
  • Table 86. Italy Biomarker Technologies, by Product USD Million (2017-2022)
  • Table 87. Italy Biomarker Technologies, by Disease Indication USD Million (2017-2022)
  • Table 88. United Kingdom Biomarker Technologies, by Type USD Million (2017-2022)
  • Table 89. United Kingdom Biomarker Technologies, by Application USD Million (2017-2022)
  • Table 90. United Kingdom Biomarker Technologies, by Product USD Million (2017-2022)
  • Table 91. United Kingdom Biomarker Technologies, by Disease Indication USD Million (2017-2022)
  • Table 92. Netherlands Biomarker Technologies, by Type USD Million (2017-2022)
  • Table 93. Netherlands Biomarker Technologies, by Application USD Million (2017-2022)
  • Table 94. Netherlands Biomarker Technologies, by Product USD Million (2017-2022)
  • Table 95. Netherlands Biomarker Technologies, by Disease Indication USD Million (2017-2022)
  • Table 96. Rest of Europe Biomarker Technologies, by Type USD Million (2017-2022)
  • Table 97. Rest of Europe Biomarker Technologies, by Application USD Million (2017-2022)
  • Table 98. Rest of Europe Biomarker Technologies, by Product USD Million (2017-2022)
  • Table 99. Rest of Europe Biomarker Technologies, by Disease Indication USD Million (2017-2022)
  • Table 100. MEA Biomarker Technologies, by Country USD Million (2017-2022)
  • Table 101. MEA Biomarker Technologies, by Type USD Million (2017-2022)
  • Table 102. MEA Biomarker Technologies, by Application USD Million (2017-2022)
  • Table 103. MEA Biomarker Technologies, by Product USD Million (2017-2022)
  • Table 104. MEA Biomarker Technologies, by Disease Indication USD Million (2017-2022)
  • Table 105. Middle East Biomarker Technologies, by Type USD Million (2017-2022)
  • Table 106. Middle East Biomarker Technologies, by Application USD Million (2017-2022)
  • Table 107. Middle East Biomarker Technologies, by Product USD Million (2017-2022)
  • Table 108. Middle East Biomarker Technologies, by Disease Indication USD Million (2017-2022)
  • Table 109. Africa Biomarker Technologies, by Type USD Million (2017-2022)
  • Table 110. Africa Biomarker Technologies, by Application USD Million (2017-2022)
  • Table 111. Africa Biomarker Technologies, by Product USD Million (2017-2022)
  • Table 112. Africa Biomarker Technologies, by Disease Indication USD Million (2017-2022)
  • Table 113. North America Biomarker Technologies, by Country USD Million (2017-2022)
  • Table 114. North America Biomarker Technologies, by Type USD Million (2017-2022)
  • Table 115. North America Biomarker Technologies, by Application USD Million (2017-2022)
  • Table 116. North America Biomarker Technologies, by Product USD Million (2017-2022)
  • Table 117. North America Biomarker Technologies, by Disease Indication USD Million (2017-2022)
  • Table 118. United States Biomarker Technologies, by Type USD Million (2017-2022)
  • Table 119. United States Biomarker Technologies, by Application USD Million (2017-2022)
  • Table 120. United States Biomarker Technologies, by Product USD Million (2017-2022)
  • Table 121. United States Biomarker Technologies, by Disease Indication USD Million (2017-2022)
  • Table 122. Canada Biomarker Technologies, by Type USD Million (2017-2022)
  • Table 123. Canada Biomarker Technologies, by Application USD Million (2017-2022)
  • Table 124. Canada Biomarker Technologies, by Product USD Million (2017-2022)
  • Table 125. Canada Biomarker Technologies, by Disease Indication USD Million (2017-2022)
  • Table 126. Mexico Biomarker Technologies, by Type USD Million (2017-2022)
  • Table 127. Mexico Biomarker Technologies, by Application USD Million (2017-2022)
  • Table 128. Mexico Biomarker Technologies, by Product USD Million (2017-2022)
  • Table 129. Mexico Biomarker Technologies, by Disease Indication USD Million (2017-2022)
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Biomarker Technologies: by Type(USD Million)
  • Table 141. Biomarker Technologies Safety Biomarkers , by Region USD Million (2023-2028)
  • Table 142. Biomarker Technologies Efficacy Biomarkers [Predictive Biomarkers, Prognostic Biomarkers, Pharmacodynamic Biomarkers, Surrogate Biomarkers] , by Region USD Million (2023-2028)
  • Table 143. Biomarker Technologies Validation Biomarkers , by Region USD Million (2023-2028)
  • Table 144. Biomarker Technologies: by Application(USD Million)
  • Table 145. Biomarker Technologies Diagnostics , by Region USD Million (2023-2028)
  • Table 146. Biomarker Technologies Personalized Medicine , by Region USD Million (2023-2028)
  • Table 147. Biomarker Technologies Drug Discovery and Development , by Region USD Million (2023-2028)
  • Table 148. Biomarker Technologies Disease Risk Assessment , by Region USD Million (2023-2028)
  • Table 149. Biomarker Technologies Others , by Region USD Million (2023-2028)
  • Table 150. Biomarker Technologies: by Product(USD Million)
  • Table 151. Biomarker Technologies Consumables , by Region USD Million (2023-2028)
  • Table 152. Biomarker Technologies Services , by Region USD Million (2023-2028)
  • Table 153. Biomarker Technologies Software , by Region USD Million (2023-2028)
  • Table 154. Biomarker Technologies: by Disease Indication(USD Million)
  • Table 155. Biomarker Technologies Cancer , by Region USD Million (2023-2028)
  • Table 156. Biomarker Technologies Neurological Disorders , by Region USD Million (2023-2028)
  • Table 157. Biomarker Technologies Cardiovascular Disorders , by Region USD Million (2023-2028)
  • Table 158. Biomarker Technologies Immunological Disorders , by Region USD Million (2023-2028)
  • Table 159. Biomarker Technologies Others , by Region USD Million (2023-2028)
  • Table 160. South America Biomarker Technologies, by Country USD Million (2023-2028)
  • Table 161. South America Biomarker Technologies, by Type USD Million (2023-2028)
  • Table 162. South America Biomarker Technologies, by Application USD Million (2023-2028)
  • Table 163. South America Biomarker Technologies, by Product USD Million (2023-2028)
  • Table 164. South America Biomarker Technologies, by Disease Indication USD Million (2023-2028)
  • Table 165. Brazil Biomarker Technologies, by Type USD Million (2023-2028)
  • Table 166. Brazil Biomarker Technologies, by Application USD Million (2023-2028)
  • Table 167. Brazil Biomarker Technologies, by Product USD Million (2023-2028)
  • Table 168. Brazil Biomarker Technologies, by Disease Indication USD Million (2023-2028)
  • Table 169. Argentina Biomarker Technologies, by Type USD Million (2023-2028)
  • Table 170. Argentina Biomarker Technologies, by Application USD Million (2023-2028)
  • Table 171. Argentina Biomarker Technologies, by Product USD Million (2023-2028)
  • Table 172. Argentina Biomarker Technologies, by Disease Indication USD Million (2023-2028)
  • Table 173. Rest of South America Biomarker Technologies, by Type USD Million (2023-2028)
  • Table 174. Rest of South America Biomarker Technologies, by Application USD Million (2023-2028)
  • Table 175. Rest of South America Biomarker Technologies, by Product USD Million (2023-2028)
  • Table 176. Rest of South America Biomarker Technologies, by Disease Indication USD Million (2023-2028)
  • Table 177. Asia Pacific Biomarker Technologies, by Country USD Million (2023-2028)
  • Table 178. Asia Pacific Biomarker Technologies, by Type USD Million (2023-2028)
  • Table 179. Asia Pacific Biomarker Technologies, by Application USD Million (2023-2028)
  • Table 180. Asia Pacific Biomarker Technologies, by Product USD Million (2023-2028)
  • Table 181. Asia Pacific Biomarker Technologies, by Disease Indication USD Million (2023-2028)
  • Table 182. China Biomarker Technologies, by Type USD Million (2023-2028)
  • Table 183. China Biomarker Technologies, by Application USD Million (2023-2028)
  • Table 184. China Biomarker Technologies, by Product USD Million (2023-2028)
  • Table 185. China Biomarker Technologies, by Disease Indication USD Million (2023-2028)
  • Table 186. Japan Biomarker Technologies, by Type USD Million (2023-2028)
  • Table 187. Japan Biomarker Technologies, by Application USD Million (2023-2028)
  • Table 188. Japan Biomarker Technologies, by Product USD Million (2023-2028)
  • Table 189. Japan Biomarker Technologies, by Disease Indication USD Million (2023-2028)
  • Table 190. India Biomarker Technologies, by Type USD Million (2023-2028)
  • Table 191. India Biomarker Technologies, by Application USD Million (2023-2028)
  • Table 192. India Biomarker Technologies, by Product USD Million (2023-2028)
  • Table 193. India Biomarker Technologies, by Disease Indication USD Million (2023-2028)
  • Table 194. South Korea Biomarker Technologies, by Type USD Million (2023-2028)
  • Table 195. South Korea Biomarker Technologies, by Application USD Million (2023-2028)
  • Table 196. South Korea Biomarker Technologies, by Product USD Million (2023-2028)
  • Table 197. South Korea Biomarker Technologies, by Disease Indication USD Million (2023-2028)
  • Table 198. Taiwan Biomarker Technologies, by Type USD Million (2023-2028)
  • Table 199. Taiwan Biomarker Technologies, by Application USD Million (2023-2028)
  • Table 200. Taiwan Biomarker Technologies, by Product USD Million (2023-2028)
  • Table 201. Taiwan Biomarker Technologies, by Disease Indication USD Million (2023-2028)
  • Table 202. Australia Biomarker Technologies, by Type USD Million (2023-2028)
  • Table 203. Australia Biomarker Technologies, by Application USD Million (2023-2028)
  • Table 204. Australia Biomarker Technologies, by Product USD Million (2023-2028)
  • Table 205. Australia Biomarker Technologies, by Disease Indication USD Million (2023-2028)
  • Table 206. Rest of Asia-Pacific Biomarker Technologies, by Type USD Million (2023-2028)
  • Table 207. Rest of Asia-Pacific Biomarker Technologies, by Application USD Million (2023-2028)
  • Table 208. Rest of Asia-Pacific Biomarker Technologies, by Product USD Million (2023-2028)
  • Table 209. Rest of Asia-Pacific Biomarker Technologies, by Disease Indication USD Million (2023-2028)
  • Table 210. Europe Biomarker Technologies, by Country USD Million (2023-2028)
  • Table 211. Europe Biomarker Technologies, by Type USD Million (2023-2028)
  • Table 212. Europe Biomarker Technologies, by Application USD Million (2023-2028)
  • Table 213. Europe Biomarker Technologies, by Product USD Million (2023-2028)
  • Table 214. Europe Biomarker Technologies, by Disease Indication USD Million (2023-2028)
  • Table 215. Germany Biomarker Technologies, by Type USD Million (2023-2028)
  • Table 216. Germany Biomarker Technologies, by Application USD Million (2023-2028)
  • Table 217. Germany Biomarker Technologies, by Product USD Million (2023-2028)
  • Table 218. Germany Biomarker Technologies, by Disease Indication USD Million (2023-2028)
  • Table 219. France Biomarker Technologies, by Type USD Million (2023-2028)
  • Table 220. France Biomarker Technologies, by Application USD Million (2023-2028)
  • Table 221. France Biomarker Technologies, by Product USD Million (2023-2028)
  • Table 222. France Biomarker Technologies, by Disease Indication USD Million (2023-2028)
  • Table 223. Italy Biomarker Technologies, by Type USD Million (2023-2028)
  • Table 224. Italy Biomarker Technologies, by Application USD Million (2023-2028)
  • Table 225. Italy Biomarker Technologies, by Product USD Million (2023-2028)
  • Table 226. Italy Biomarker Technologies, by Disease Indication USD Million (2023-2028)
  • Table 227. United Kingdom Biomarker Technologies, by Type USD Million (2023-2028)
  • Table 228. United Kingdom Biomarker Technologies, by Application USD Million (2023-2028)
  • Table 229. United Kingdom Biomarker Technologies, by Product USD Million (2023-2028)
  • Table 230. United Kingdom Biomarker Technologies, by Disease Indication USD Million (2023-2028)
  • Table 231. Netherlands Biomarker Technologies, by Type USD Million (2023-2028)
  • Table 232. Netherlands Biomarker Technologies, by Application USD Million (2023-2028)
  • Table 233. Netherlands Biomarker Technologies, by Product USD Million (2023-2028)
  • Table 234. Netherlands Biomarker Technologies, by Disease Indication USD Million (2023-2028)
  • Table 235. Rest of Europe Biomarker Technologies, by Type USD Million (2023-2028)
  • Table 236. Rest of Europe Biomarker Technologies, by Application USD Million (2023-2028)
  • Table 237. Rest of Europe Biomarker Technologies, by Product USD Million (2023-2028)
  • Table 238. Rest of Europe Biomarker Technologies, by Disease Indication USD Million (2023-2028)
  • Table 239. MEA Biomarker Technologies, by Country USD Million (2023-2028)
  • Table 240. MEA Biomarker Technologies, by Type USD Million (2023-2028)
  • Table 241. MEA Biomarker Technologies, by Application USD Million (2023-2028)
  • Table 242. MEA Biomarker Technologies, by Product USD Million (2023-2028)
  • Table 243. MEA Biomarker Technologies, by Disease Indication USD Million (2023-2028)
  • Table 244. Middle East Biomarker Technologies, by Type USD Million (2023-2028)
  • Table 245. Middle East Biomarker Technologies, by Application USD Million (2023-2028)
  • Table 246. Middle East Biomarker Technologies, by Product USD Million (2023-2028)
  • Table 247. Middle East Biomarker Technologies, by Disease Indication USD Million (2023-2028)
  • Table 248. Africa Biomarker Technologies, by Type USD Million (2023-2028)
  • Table 249. Africa Biomarker Technologies, by Application USD Million (2023-2028)
  • Table 250. Africa Biomarker Technologies, by Product USD Million (2023-2028)
  • Table 251. Africa Biomarker Technologies, by Disease Indication USD Million (2023-2028)
  • Table 252. North America Biomarker Technologies, by Country USD Million (2023-2028)
  • Table 253. North America Biomarker Technologies, by Type USD Million (2023-2028)
  • Table 254. North America Biomarker Technologies, by Application USD Million (2023-2028)
  • Table 255. North America Biomarker Technologies, by Product USD Million (2023-2028)
  • Table 256. North America Biomarker Technologies, by Disease Indication USD Million (2023-2028)
  • Table 257. United States Biomarker Technologies, by Type USD Million (2023-2028)
  • Table 258. United States Biomarker Technologies, by Application USD Million (2023-2028)
  • Table 259. United States Biomarker Technologies, by Product USD Million (2023-2028)
  • Table 260. United States Biomarker Technologies, by Disease Indication USD Million (2023-2028)
  • Table 261. Canada Biomarker Technologies, by Type USD Million (2023-2028)
  • Table 262. Canada Biomarker Technologies, by Application USD Million (2023-2028)
  • Table 263. Canada Biomarker Technologies, by Product USD Million (2023-2028)
  • Table 264. Canada Biomarker Technologies, by Disease Indication USD Million (2023-2028)
  • Table 265. Mexico Biomarker Technologies, by Type USD Million (2023-2028)
  • Table 266. Mexico Biomarker Technologies, by Application USD Million (2023-2028)
  • Table 267. Mexico Biomarker Technologies, by Product USD Million (2023-2028)
  • Table 268. Mexico Biomarker Technologies, by Disease Indication USD Million (2023-2028)
  • Table 269. Research Programs/Design for This Report
  • Table 270. Key Data Information from Secondary Sources
  • Table 271. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Biomarker Technologies: by Type USD Million (2017-2022)
  • Figure 5. Global Biomarker Technologies: by Application USD Million (2017-2022)
  • Figure 6. Global Biomarker Technologies: by Product USD Million (2017-2022)
  • Figure 7. Global Biomarker Technologies: by Disease Indication USD Million (2017-2022)
  • Figure 8. South America Biomarker Technologies Share (%), by Country
  • Figure 9. Asia Pacific Biomarker Technologies Share (%), by Country
  • Figure 10. Europe Biomarker Technologies Share (%), by Country
  • Figure 11. MEA Biomarker Technologies Share (%), by Country
  • Figure 12. North America Biomarker Technologies Share (%), by Country
  • Figure 13. Global Biomarker Technologies share by Players 2022 (%)
  • Figure 14. Global Biomarker Technologies share by Players (Top 3) 2022(%)
  • Figure 15. Global Biomarker Technologies share by Players (Top 5) 2022(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 18. Thermo Fisher Scientific (United States) Revenue: by Geography 2022
  • Figure 19. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 20. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2022
  • Figure 21. Agilent Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 22. Agilent Technologies (United States) Revenue: by Geography 2022
  • Figure 23. Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 24. Roche (Switzerland) Revenue: by Geography 2022
  • Figure 25. Danaher Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 26. Danaher Corporation (United States) Revenue: by Geography 2022
  • Figure 27. Merck Millipore (United States) Revenue, Net Income and Gross profit
  • Figure 28. Merck Millipore (United States) Revenue: by Geography 2022
  • Figure 29. Waters Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 30. Waters Corporation (United States) Revenue: by Geography 2022
  • Figure 31. Shimadzu Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 32. Shimadzu Corporation (Japan) Revenue: by Geography 2022
  • Figure 33. Bio-Rad Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 34. Bio-Rad Laboratories (United States) Revenue: by Geography 2022
  • Figure 35. Meso Scale Diagnostics, LLC (United States) Revenue, Net Income and Gross profit
  • Figure 36. Meso Scale Diagnostics, LLC (United States) Revenue: by Geography 2022
  • Figure 37. Global Biomarker Technologies: by Type USD Million (2023-2028)
  • Figure 38. Global Biomarker Technologies: by Application USD Million (2023-2028)
  • Figure 39. Global Biomarker Technologies: by Product USD Million (2023-2028)
  • Figure 40. Global Biomarker Technologies: by Disease Indication USD Million (2023-2028)
  • Figure 41. South America Biomarker Technologies Share (%), by Country
  • Figure 42. Asia Pacific Biomarker Technologies Share (%), by Country
  • Figure 43. Europe Biomarker Technologies Share (%), by Country
  • Figure 44. MEA Biomarker Technologies Share (%), by Country
  • Figure 45. North America Biomarker Technologies Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Thermo Fisher Scientific (United States)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Agilent Technologies (United States)
  • Roche (Switzerland)
  • Danaher Corporation (United States)
  • Merck Millipore (United States)
  • Waters Corporation (United States)
  • Shimadzu Corporation (Japan)
  • Bio-Rad Laboratories (United States)
  • Meso Scale Diagnostics, LLC (United States)
Select User Access Type

Key Highlights of Report


May 2023 227 Pages 84 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Biomarker Technologies Quantitative research analysis
Global Biomarker Technologies Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2018-2022; Base year: 2022; Forecast period: 2023 to 2028
Companies that are profiled in Global Biomarker Technologies Market are Thermo Fisher Scientific (United States), F. Hoffmann-La Roche Ltd (Switzerland), Agilent Technologies (United States), Roche (Switzerland), Danaher Corporation (United States), Merck Millipore (United States), Waters Corporation (United States), Shimadzu Corporation (Japan), Bio-Rad Laboratories (United States) and Meso Scale Diagnostics, LLC (United States) etc.
Diagnostics segment in Global market to hold robust market share owing to "Increasing Diagnostic Applications of Biomarkers Technologies ".
AMA Research predicts that United States Players will contribute to the maximum growth of Global Biomarker Technologies market throughout the forecasted period.

Know More About Global Biomarker Technologies Report?

Have a Query? Click Here

Other Related Reports

Veterinary Molecular Diagnostics Comprehensive Study by Type (Instruments, Consumables), Application (Livestock Animals, Companion Animals), Disease Type (Infectious Diseases, Oncology, Genetics, Mic...
$ 3750
Biochips Comprehensive Study by Type (DNA Chips, Protein Chips, Lab-on-a-Chip, Others), Application (Drug Discovery & Development, Disease Diagnostics, Genomics, Proteomics, Agriculture, Others), End...
$ 3650
Phycocyanin Comprehensive Study by Application (Natural colourant, Pharmaceuticals), Nature (Organic, Conventional), Form (Powder, Liquid) Players and Region - Global Market Outlook to 2027
$ 3500
Cell Proliferation Kit Comprehensive Study by Type (Colorimetric Detection Method, Fluorescent Detection Method, Other), Application (Clinical, Industrial & Applied Science, Stem Cell Research), Cell...
$ 3350
Marine Biotechnology Comprehensive Study by Type (Marine Animal Technolog, Marine Plant Technology), Application (Cosmetics, Pharmaceuticals, Fine Chemical, Nutritional Supplements), Source (Algae, A...
$ 3450
Rat Model Comprehensive Study by Type (Inbred, Outbred, Knockout, Hybrid, Others), Application (Research and Development (Infectious Disease, Immunological Diseases, Cancer, Cardiovascular Diseases, ...
$ 3650